An Arizona couple whose son was diagnosed with a rare genetic condition that causes progressive vision loss have now directed $7.1 million towards research into inherited retinal diseases. Dr Stephen Johnston and his wife, Kristina Johnston, founded the nonprofit organisation A Race Against Blindness after their son Luke was diagnosed with Bardet-Biedl syndrome in 2020. What began as a family’s effort to find a treatment for their child has since grown into a wider research-funding mission, supporting both gene-specific and gene-agnostic approaches to tackling inherited blindness. The organisation announced its latest $1 million commitment in November 2026, taking its total research grants to $7.1 million, all of which it says has been paid out.
A son’s rare eye disease inspires parents’ $7.1 million mission
Bardet-Biedl syndrome (BBS) is a rare genetic disorder that can affect several parts of the body, including the eyes. In Luke’s case, the condition caused retinitis pigmentosa (RP), a group of inherited retinal disorders in which light-sensitive cells in the retina gradually deteriorate. Vision loss can begin with difficulty seeing in low light and progress to a reduction in peripheral vision, potentially leading to severe visual impairment.The Johnstons said they were told there was little that could be done for their son’s condition. Rather than accept that as the end of the search for answers, they decided to help fund research into possible treatments. They established A Race Against Blindness in 2023, turning their family’s experience into an effort to support children and families affected by inherited retinal diseases.
How the $7.1 million will support research
The organisation’s latest commitment, announced on November 17, 2026, is a $1 million grant made in partnership with the Foundation Fighting Blindness. The money has been divided between two research initiatives:$700,000 to the Gund Vision Fund: The amount will be matched dollar for dollar by the Gordon and Llura Gund Foundation Challenge, taking the total support for the fund to $1.4 million. It will back several gene-agnostic approaches, including research into protecting retinal cells, restoring light sensitivity and developing cell therapies.$300,000 for research led by Dr Jin Woo Kim at the Korea Advanced Institute of Science and Technology (KAIST): The funding will support preclinical work investigating whether the retina’s own cells can be encouraged to regenerate.The latest grant follows an earlier $1 million commitment in June 2026, also made through the Foundation Fighting Blindness and the Gund Vision Fund. That funding included $775,000 for the fund, which was matched to $1.55 million, and $225,000 for research led by Dr Thomas Mendel at The Ohio State University.
Research aims to help the retina regenerate
One of the projects receiving the latest funding focuses on a protein called PROX1. Dr Kim’s research examines how this protein affects Müller glia, support cells in the retina that have the potential to develop into new retinal cells under certain conditions.A study published in Nature Communications on March 25, 2025, found that PROX1 can restrict the regenerative potential of these cells. Researchers reported that blocking the transfer of PROX1 between retinal cells allowed Müller glia to reprogramme into retinal progenitor cells in injured mouse retinas. In experiments involving mice with retinitis pigmentosa, an antibody designed to block PROX1 promoted the regeneration of retinal neurons and delayed vision loss.The findings offer a possible direction for future treatments, but the research is still at the preclinical stage. The latest funding is intended to help refine the antibody and its delivery, with further studies, including large-animal research, needed before the approach could be considered for human trials. It is not an established treatment for people with inherited retinal diseases.
$5.1 million directed towards a gene therapy for Luke’s condition
Before expanding its focus to treatments that could benefit people with different inherited retinal diseases, A Race Against Blindness had concentrated on finding a therapy for the specific genetic condition affecting Luke.The organisation provided $5.1 million to support the development of AXV-101, an experimental gene therapy designed for retinal degeneration associated with mutations in the BBS1 gene. The funding supported work including manufacturing, safety studies and the steps required to move the treatment into clinical testing.The therapy has now entered a first-in-human clinical trial, designed to assess its preliminary safety and tolerability in children with BBS1-related retinal degeneration. The early-stage study is expected to enrol up to 12 participants aged between four and 17. It is an important research milestone, but the trial is not yet evidence that the therapy can restore eyesight.
From a family fundraiser to a wider research mission
The Johnstons established A Race Against Blindness in 2023, with their own fundraising efforts helping launch the organisation. One of its early initiatives involved donating a custom adventure van as a sweepstakes prize to raise money for research.Since then, the nonprofit has expanded its support beyond BBS1-related treatments to include approaches that could potentially help people with several forms of inherited retinal disease. According to its published grant record, its $7.1 million in research funding comprises $5.1 million for AXV-101 and another $2 million for gene-agnostic research through the Foundation Fighting Blindness and its Gund Vision Fund.
Discover more from updatview
Subscribe to get the latest posts sent to your email.